240 completed, 172 recruiting, 151 unknown, 98 terminated. 343 Phase 2, 166 Phase 1, 143 Not applicable, 55 Phase 3, 12 Phase 4.
Follow Cholangiocarcinoma: new trials by email Literature Review of Cholangiocarcinoma trials Research Report on Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Incyte Corporation | 72 | 2026-12-15 | 2026-10-20 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma 3D185 - Cholangiocarcinoma,Adult | Phase 2 | Not yet recruiting | 3D Medicines (Beijing) Co., Ltd. | 50 | 2026-12-01 | 2026-09-09 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 3 | Not yet recruiting | Zhai Wenlong | 90 | 2026-11-30 | 2026-11-04 |
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib - Colorectal Neoplasms, Neoplasms | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 20 | 2026-11-15 | 2026-11-10 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer | Phase 1 | Not yet recruiting | Iksuda Therapeutics Ltd. | 120 | 2026-11-01 | 2026-07-31 |
| Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma Histotripsy, Durvalumab, Biopsy - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | University of Wisconsin, Madison | 12 | 2026-11-01 | 2026-10-30 |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-11-10 |
| [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging - Cholangiocarcinoma | Phase 2 | Recruiting | University of Washington | 22 | 2026-10-08 | 2026-10-20 |
| Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma Anlotinib, TQB2868 Injection, cryoablation - Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 56 | 2026-10-01 | 2026-09-29 |
| Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer Three-Dimensional Magnetic Resonance Elastography - Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma | Not yet recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 100 | 2026-10-01 | 2026-07-21 | |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-10-01 | 2026-10-29 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-28 |
| A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin, Pembrolizumab + Gemcitabine/Cisplatin - Intrahepatic Cholangiocarcinoma (Icc) | Phase 1 / Phase 2 | Not yet recruiting | Shanghai 6th People's Hospital | 112 | 2026-09-15 | 2026-08-28 |
| Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc) | Phase 3 | Not yet recruiting | Zhejiang Cancer Hospital | 140 | 2026-09-01 | 2026-10-26 |
| Prognostic Evaluation and Systematic Re-Assessment of Cholangiocarcinoma Therapy Intrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma | Not yet recruiting | Karolinska University Hospital | 900 | 2026-09-01 | 2026-09-11 | |
| EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis EYEMAX® cholangioscopy system, SPYGLASS™ DS system - Cholangiocarcinoma, Biliary Stricture | Not applicable | Not yet recruiting | David KARSENTI | 120 | 2026-09-01 | 2026-06-02 |
Showing 20 of 825. Sign in to see all of them.
Pancreatic Neoplasms (126) · Carcinoma, Hepatocellular (117) · Gallbladder Neoplasms (113) · Biliary Tract Neoplasms (100) · Colorectal Neoplasms (88) · Klatskin Tumor (80) · Liver Neoplasms (76) · Bile Duct Neoplasms (75) · Stomach Neoplasms (74) · Ovarian Neoplasms (53) · Breast Neoplasms (52) · Carcinoma, Non-Small-Cell Lung (51) · Esophageal Neoplasms (46) · Neoplasms (45)
Neoplasms by Histologic Type (825) · Neoplasms, Glandular and Epithelial (825) · Adenocarcinoma (816) · Carcinoma (812) · Neoplasms (780) · Digestive System Diseases (456) · Neoplasms by Site (445) · Digestive System Neoplasms (430) · Biliary Tract Diseases (246) · Endocrine Gland Neoplasms (166) · Endocrine System Diseases (166) · Liver Diseases (162) · Gastrointestinal Diseases (148) · Gastrointestinal Neoplasms (133) · Pancreatic Diseases (130)
Gemcitabine (119) · Cisplatin (82) · Oxaliplatin (47) · pembrolizumab (39) · Capecitabine (37) · Fluorouracil (35) · durvalumab (30) · lenvatinib (28) · Leucovorin (27) · Magnetic Resonance Spectroscopy (18) · Biopsy (14) · Irinotecan (14) · Drug Therapy (13) · Specimen Handling (13) · 130-nm albumin-bound paclitaxel (12)
National Cancer Institute (NCI) (23) · Shanghai Zhongshan Hospital (17) · Mayo Clinic (14) · Fudan University (13) · Tianjin Medical University Cancer Institute and Hospital (12) · M.D. Anderson Cancer Center (10) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (9) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (9) · Peking Union Medical College Hospital (8) · Sun Yat-sen University (8) · Washington University School of Medicine (8) · Weill Medical College of Cornell University (8) · City of Hope Medical Center (7) · First Affiliated Hospital Xi'an Jiaotong University (7) · First People's Hospital of Hangzhou (7)
United States (316) · China (227) · France (71) · South Korea (68) · Germany (60) · Italy (59) · Spain (51) · United Kingdom (44) · Canada (41) · Australia (38) · Netherlands (36) · Taiwan (35) · Belgium (34) · Japan (28) · Denmark (18)
Michel Kahaleh, MD (8) · Ajay Goel, PhD (5) · Chao Liu, PhD (5) · Jonathan M Hernandez, M.D. (5) · Peng Wang, MD (4) · Tim F Greten, M.D. (4) · Salah-Eddin Al-Batran, Prof. Dr. (3) · Xiaofeng Zhang, M.S (3) · Andrea Cercek, MD (2) · Anthony El-Khoueiry, MD (2)
PMID 40812353, PMID 20375404, PMID 29433850, PMID 30998813, PMID 37075781, PMID 38258823, PMID 20165987, PMID 24146220, PMID 27095655, PMID 28420720, PMID 28818953, PMID 29342492, PMID 30420614, PMID 30785198, PMID 31778656, PMID 32461347, PMID 32832493, PMID 33198671, PMID 33798493, PMID 37082579, PMID 38319896, PMID 42176183, PMID 11683741, PMID 12001988, PMID 12838220, PMID 1294807, PMID 15192785, PMID 15319238, PMID 15691639, PMID 15824939, PMID 15849514, PMID 16632990, PMID 16767908, PMID 17543307, PMID 17704903, PMID 18161934, PMID 18478290, PMID 18751418, PMID 18981929, PMID 19097774, PMID 19393505, PMID 19491285, PMID 19626372, PMID 19906081, PMID 19917863, PMID 20014463, PMID 20061178, PMID 20233873, PMID 20336386, PMID 20374484
2023 (10), 2016 (7), 2015 (6), 2025 (6), 2018 (4), 2019 (4), P30CA015083 (3), U10CA180888 (3), 2017 (2), P30CA014089 (2), P30CA138292 (2), U10CA032102 (2), U10CA180820 (2), U2CCA252981 (2), UM1CA186689 (2)